Medindia

X

Reportlinker Adds Pazopanib - Key Patent, SPC, and Data Exclusivity Expiry (44 Country Coverage)

Thursday, May 26, 2011 General News J E 4
Advertisement

NEW YORK, May 26, 2011 /PRNewswire/ --Reportlinker.com announces that a new market research report is available in its catalogue:

Pazopanib - Key patent, SPC, and data exclusivity expiry (44 country coverage)

http://www.reportlinker.com/p0507345/Pazopanib---Key-patent-SPC-and-data-exclusivity-expiry-44-country-coverage.html?utm_source=prnewswire&utm_medium=pr&utm_campaign=Pathology

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

This Pipeline Selector report covers Pazopanib

Pazopanib indications: Treatment of advanced and/or metastatic renal cell carcinoma

Pazopanib innovator: Glaxosmithkline (Votrient)

Examples of information found in this online report include:

# Includes key patent publications for 44 countries (see list below)

# Contains SPC protection for every EU state plus patent term extensions in other countries

# Data exclusivity calculated on a country by country basis

# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product

# DMF & Paragraph IV filings

# Litigation alerts

# Marketing authorisation holders in selected territories

# Patent risk analysis via graphical display of data from patent filings

# Hyper-linking to crucial patent documents and national registries enabling data verification

The 'Key Patent Indicator' enables easy identification of key patent, SPC and data protection expiry information covering 44 countries, including extension details (SPC and national law) for 30 European countries, Australia, Israel, Japan and the USA. (also available with 44 country coverage):

Pipeline Selector 44 Country Coverage:

Country Region Extensions

Australia Asia-Pacific S70

Canada Americas N/A

USA Americas S156

Germany Western Europe SPC

Great Britain Western Europe SPCS

France Western Europe NAT/SPC

Spain Western Europe SPC

South Africa Africa N/A

China Asia-Pacific N/A

Japan Asia-Pacific S67

New Zealand Asia-Pacific N/A

Bosnia & Herzegovina Balkan N/A

Bulgaria Balkan SPC

Croatia Balkan N/A

Romania Balkan SPC

Slovenia Balkan NAT/SPC

Estonia Baltic NAT/SPC

Lithuania Baltic NAT/SPC

Latvia Baltic NAT/SPC

Czech Republic Central Europe NAT/SPC

Hungary Central Europe SPC

Poland Central Europe SPC

Slovakia Central Europe NAT/SPC

Serbia & Montenegro Central Europe N/A

Cyprus Mediterranean NAT/SPC

Greece Mediterranean SPC

Israel Mediterranean NAT

Malta Mediterranean SPC

Turkey Mediterranean N/A

Denmark Scandinavia SPC

Finland Scandinavia SPC

Iceland Scandinavia SPC

Norway Scandinavia SPC

Sweden Scandinavia SPC

Brazil South America N/A

Mexico South America N/A

Austria Western Europe SPC

Belgium Western Europe SPC

Switzerland Western Europe NAT/SPC

Ireland Western Europe SPC

Italy Western Europe NAT/SPC

Luxembourg Western Europe SPC

The Netherlands Western Europe SPC

Portugal Western Europe SPC

Other key information contained in the report:

# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product in major countries**.

# News articles

# Litigation alerts

# Marketing authorisation holders for Great Britain, the United States, Canada and Australia enable you to see who is active in the market.

# US Drug Master Files, providing valuable information to help source active ingredients and keep an eye on competitors.

# Paragraph IV filing; details of US ANDAs filed with a Paragraph IV certification allow easy determination of who the first movers are for a particular generic product in the US.

# 'Patent Risk Analysis' section containing three graphical displays of data drawn from known patent filings to provide valuable competitor insight and development information***.

*Key Patent Indicator

The 'Key Patent Indicator' section is intended only to provide an indication of the Key Patents pertaining to a generic drug, and is not based on a comprehensive patent search (a comprehensive patent search can be found in the corresponding Pipeline Selector report).

**General Drug Information

Information contained in 'General Indications' and 'Brand Product Attributes' is based on products containing the active pharmaceutical ingredient, which are currently registered in Australia, UK and the USA. Indications are summarised where appropriate and may vary between individual countries.

***Patent Risk Analysis

The three graphical analyses are based on data contained in our Pipeline Selector comprehensive patent search, and thus are subject to its scope and limitations. These graphics are intended to provide only a summary of the patent filings; specific details of the filings should be investigated through the use of the Pipeline Selector reports.

Pipeline Selector is just one of the benchmark products from GenericsWeb's Pipeline Patent Intelligence product suite.

Pipeline Selector helps you avoid hours of painstaking research by quickly providing you with an accurate snapshot of a single INN, including key patents, extensions and data exclusivity expiry for 44 countries (7 country coverage also available), regulatory issues and key players.

# Includes key patent publications for 44 countries

# Contains SPC protection for every EU state plus patent term extensions in other countries

# Data exclusivity calculated on a country by country basis

# Summary of dosage forms, strengths, indications and active ingredient forms of the brand product

# DMF & Paragraph IV filings

# Litigation alerts

# Marketing authorisation holders in selected territories

# Patent risk analysis via graphical display of data from patent filings

# Hyper-linking to crucial patent documents and national registries enabling data verification

To order this report:

Pathology Industry: Pazopanib - Key patent, SPC, and data exclusivity expiry (44 country coverage)

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Nicolas BombourgReportlinkerEmail: nbo@reportlinker.comUS: (805)652-2626Intl: +1 805-652-2626

SOURCE Reportlinker

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Reportlinker Adds Vildagliptin - Key Patent, SPC, ...
S
Genetic Technologies Files New Patent Infringement...